With the progress of modern medicine, various advanced treatment methods have brought good news to many tumor patients, but there are still a considerable number of advanced tumor patients who have no effect on conventional treatment methods, and then drug clinical trials can bring them a last hope. GCP, the Chinese name of which is “Drug Clinical Trial Quality Management Standard”, is a standard regulation that regulates the whole process of drug clinical trials, which aims to ensure the standardization of clinical trial process, scientific and reliable results, protect the rights and interests of subjects and safeguard their safety. It has been nearly a decade since the introduction, promotion and implementation of GCP in China. The development of a new anti-cancer drug, from pre-clinical trials to approval for clinical trials and then to market generally takes 7 to 10 years, which for a patient with advanced cancer, it is difficult to have the opportunity to wait for the day when the drug is marketed without participating in clinical trials. Therefore, if a patient with advanced cancer can have the opportunity to join a clinical trial of a new drug, it is like opening a door to life for someone who is in a desperate situation. Many volunteers who are successfully recruited will be concerned about safety issues, after all, the new drug is not applied to the majority of cancer patients. It should be emphasized that clinical trials are not the mice trials that the people imagine. Drugs must go through a gradual process of Phase I, Phase II, and Phase III, and Phase III is the final stage before going to market, and generally go through a trial process with hundreds or thousands of patients. Moreover, patients have the right to withdraw from the trial at any time if they have questions about the drug trial after enrollment. Before each new drug enters the urology GCP center for clinical drug trials, its parent supervisory authority, the Ethics Committee of Xinhua Hospital, conducts a strict ethical review to ensure that human rights are respected and that patients are considered from the perspective of whether they can benefit. Especially for volunteers who discontinue drugs due to adverse reactions, the ethics committee will supervise their later recovery and pay more attention to the potential risks and effects brought to other patients as a result, fully protecting the rights and interests of each patient. The fight against tumors is a long and arduous process, and the research and development of various anti-cancer drugs is also in constant development and progress. Experts around the world have long reached a consensus on drug clinical trials, that is, to encourage patients with advanced tumors to actively participate in clinical research when conditions are available, because clinical research has the strongest and best treatment in the world, and it is an important part of the medical treatment process.